Valuation: Vistagen Therapeutics, Inc.

Market Cap 10.37M 9.04M 8.54M 7.75M 14.52M 995M 14.58M 102M 39.45M 506M 38.94M 38.08M 1.63B P/E 2027 *
-0.16x
P/E 2028 * -0.15x
Enterprise Value -184M -161M -152M -138M -258M -17.69B -259M -1.82B -702M -8.99B -692M -677M -28.94B EV / Sales 2027 *
-109x
EV / Sales 2028 * -
Free-Float
99.62%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Vistagen Therapeutics, Inc.

1 day+3.17%
1 week+1.77%
Current month-5.41%
1 month-0.33%
3 months-64.01%
6 months-60.46%
Current year-63.56%
1 week 0.23
Extreme 0.226
0.25
1 month 0.23
Extreme 0.226
0.27
Current year 0.2
Extreme 0.198
0.8
1 year 0.2
Extreme 0.198
5.14
3 years 0.2
Extreme 0.198
5.86
5 years 0.2
Extreme 0.198
89.4
10 years 0.2
Extreme 0.198
140.7
Manager TitleAgeSince
Chief Executive Officer 63 2009-07-31
Director of Finance/CFO 53 2025-11-30
Chief Tech/Sci/R&D Officer 57 2026-05-17
Director TitleAgeSince
Director/Board Member 63 1999-12-31
Chairman 90 2000-05-31
Director/Board Member 58 2019-01-09
Date Insider Type Main position Quantity % Market Cap. Importance
7/29/26 Free

Director

40,826 0.0995%
6/30/26 Free

Chief Executive Officer

36,818 0.0897%
6/30/26 Free

Chief Financial Officer

11,712 0.0285%
Change 5-day change 1-year change 3-year change Capi.($)
+3.17%+1.77%-92.07%-95.75% 10.37M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+2.06%+40.91%+78.49% 62.32B
-2.20%-6.43%-16.98%+356.08% 27.07B
-2.54%-0.65%-0.21%-11.86% 24.78B
+0.71%+8.03%+27.22%-13.18% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.91%+3.40%+43.46%+171.80% 14.49B
-0.93%-0.03%-8.76%+869.34% 14.14B
-0.77%-1.43%+19.54%+222.08% 12.35B
Average -0.46%+1.29%+23.02%+196.80% 26.22B
Weighted average by Cap. -0.61%+1.39%+35.59%+164.47%

Financials

2027 *2028 *
Net sales 1.69M 1.47M 1.39M 1.26M 2.36M 162M 2.37M 16.65M 6.42M 82.35M 6.34M 6.2M 265M -
Net income -61.56M -53.68M -50.69M -46.03M -86.23M -5.91B -86.59M -607M -234M -3B -231M -226M -9.66B -65.79M -57.37M -54.17M -49.19M -92.16M -6.31B -92.54M -649M -250M -3.21B -247M -242M -10.33B
Net Debt -195M -170M -160M -146M -273M -18.68B -274M -1.92B -741M -9.5B -731M -715M -30.56B -
Logo Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Employees
41
Date Price Change Volume
26-09-18 US$0.2413 +3.30% 356,930
26-09-17 US$0.2336 +1.30% 369,919
26-09-16 US$0.2306 -2.33% 553,566
26-09-15 US$0.2361 -2.92% 194,442
26-09-14 US$0.2432 +2.62% 239,362
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.2336USD
Average target price
1.000USD
Spread / Average Target
+328.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTGN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!